How much funding has AN2 Therapeutics raised?

AN2 Therapeutics has raised $52.0M in total funding, most recently a Private Equity round.

Who are AN2 Therapeutics's investors?

AN2 Therapeutics's investors include Mountain Partners, Coastlands Capital, Commodore Capital, Vivo Capital, Adjuvant Capital.

When was AN2 Therapeutics founded?

AN2 Therapeutics was founded in 2017.

Where is AN2 Therapeutics headquartered?

AN2 Therapeutics is headquartered in Menlo Park, United States.

What industry is AN2 Therapeutics in?

AN2 Therapeutics operates in Biotech, Healthcare.

AN2 Therapeutics

IPO

Developing Therapies for Rare, Chronic, and Serious Infectious Diseases

Public · Menlo Park, United States · Founded 2017 · $52.0M raised

Biotech

Healthcare

Headquarters: Menlo Park
Founded: 2017
Business Model: B2B
Website: an2therapeutics.com

Total Funding: $52.0M
Last Round: $40.0M Private EquityMar 2026
Rounds: 2
Type: Public

About

AN2 Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: ANTX) focused on the discovery, development, and commercialization of novel medicines for rare, chronic, and serious infectious diseases with significant unmet patient need. The founding team has a track record of pairing strategic partnerships and non-dilutive funding to advance global public health programs alongside its core clinical pipeline. AN2 is headquartered in Menlo Park, California.

Summary

AN2 Therapeutics is a Biotech company based in Menlo Park, United States, founded in 2017. It has raised $52.0M in total across 2 rounds, most recently a $40.0M Private Equity round in Mar 2026. Investors include Mountain Partners, Coastlands Capital and Commodore Capital.